Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that remains despite treatment (resistant). Lutetium Lu 177 (177Lu), the radioactive (tracer) component being delivered by prostate-specific membrane antigen (PSMA)-617, has physical properties that make it ideal radionuclide (imaging tests that uses a small dose tracer) for treatment of metastatic castrate-resistant prostate cancer (mCRPC). 177Lu-PSMA-617 works by binding to prostate cancer cells and inducing damage to deoxyribonucleic acid (DNA) inside prostate cancer cells. Giving 177Lu-PSMA-617 may improve treatment outcomes for patients with mCRPC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent ma ukończone 18 lat.
- •Pacjent jest w stanie zrozumieć i podpisać zgodę na udział w badaniu.
- •Pacjent potwierdza raka prostaty po badaniach.
- •Wyniki badania obrazowego (PET/CT) wskazują na obecność komórek rakowych reagujących na lek.
- •Wcześniejsze leczenie hormonalne i obniżony poziom testosteronu.
- •Pacjent przyjmował co najmniej jeden z określonych leków hormonalnych (np. enzalutamid, abirateron).
- •Choroba nowotworowa postępuje mimo dotychczasowego leczenia.
✗ Disqualifies
- •Pacjent nie spełnia wymagań badania dotyczących aktywności życiowej.
- •Wskazania do obecności przerzutów raka prostaty, które nie reagują na lek.
- •Wskazania do zbyt wysokiego stężenia PSMA w całym organizmie według badania PET/CT.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 7, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (3)
University of California San Francisco
San Francisco, United States
Olive View-University of California Los Angeles Medical Center
Sylmar, United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, United States
Trial contact
Akshata Mathur
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.